Recurrent Ovarian Carcinoma

Showing 26 - 50 of 86

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1429 more
Aug 17, 2022

Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma Trial in Canada, Singapore, United States

Active, not recruiting
  • Ovarian Brenner Tumor
  • +11 more
  • Duarte, California
  • +15 more
Aug 11, 2022

Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)

Recruiting
  • Bone Sarcoma
  • +15 more
  • Aldesleukin
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 3, 2022

Recurrent Ovarian Carcinoma Trial in Worldwide (Bevacizumab, Atezolizumab, Chemotherapy)

Active, not recruiting
  • Recurrent Ovarian Carcinoma
  • Innsbruck, Austria
  • +110 more
Jul 25, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Biopsy
  • Pegylated SN-38 Conjugate PLX038
  • Rochester, Minnesota
    Mayo Clinic
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bevacizumab
  • +4 more
  • Phoenix, Arizona
  • +2 more
Jun 27, 2022

Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston

Recruiting
  • Malignant Female Reproductive System Neoplasm
  • +24 more
  • Quality-of-Life Assessment
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 6, 2022

Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Aurora

Active, not recruiting
  • Recurrent Endometrial Serous Adenocarcinoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Aurora, Colorado
    University of Colorado Hospital
May 24, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Metastatic Breast Cancer, Recurrent Ovarian Carcinoma Trial in Salt Lake City, Fairfax (Ribociclib, Belinostat)

Recruiting
  • Metastatic Breast Cancer
  • Recurrent Ovarian Carcinoma
  • Salt Lake City, Utah
  • +1 more
May 3, 2022

Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Shibin Al Kawm (secondary cytoreductive surgery, Chemotherapy)

Withdrawn
  • Ovarian Cancer
  • Recurrent Ovarian Carcinoma
  • Shibīn Al Kawm, Menoufia, Egypt
    Menoufia University, Faculty of medicine
Apr 9, 2022

Advanced Solid Tumors, EGFR Positive NSCLC, Colorectal Carcinoma Trial in United States (TP-0903)

Active, not recruiting
  • Advanced Solid Tumors
  • +4 more
  • Phoenix, Arizona
  • +15 more
Apr 4, 2022

Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma Trial in

Recruiting
  • Advanced Differentiated Thyroid Gland Carcinoma
  • +102 more
  • Cabozantinib S-malate
  • Nivolumab
  • Chicago, Illinois
  • +2 more
Apr 5, 2022

Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and

Recruiting
  • Ovarian Carcinoma
  • +6 more
  • Albumin-bound paclitaxel and bevacizumab
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Seattle

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Mar 10, 2022

Ovarian Serous Tumor, Recurrent Ovarian Carcinoma Trial in Rochester (Auranofin, Laboratory Biomarker Analysis, Sirolimus)

Active, not recruiting
  • Ovarian Serous Tumor
  • Recurrent Ovarian Carcinoma
  • Rochester, Minnesota
    Mayo Clinic
Mar 22, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Buffalo

Active, not recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Aldesleukin
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Mar 3, 2022

Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Beijing (6B11-OCIK Injection, Doxorubicin)

Recruiting
  • Recurrent Ovarian Carcinoma
  • Platinum-resistant Ovarian Cancer
  • Beijing, China
    Peking University People's hospital
Feb 11, 2022

Recurrent Ovarian Carcinoma Trial in Worldwide (Placebo, Carboplatin, Paclitaxel)

Active, not recruiting
  • Recurrent Ovarian Carcinoma
  • Placebo
  • +6 more
  • Charleroi, Belgium
  • +70 more
Feb 7, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States

Completed
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +44 more
Jan 10, 2022

Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Los Angeles

Recruiting
  • Recurrent Endometrial Carcinoma
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 28, 2021

Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in United States (ChemoID Assay, Standard Chemotherapy)

Recruiting
  • Recurrent Ovarian Carcinoma
  • Platinum-resistant Ovarian Cancer
  • ChemoID Assay
  • Standard Chemotherapy
  • Phoenix, Arizona
  • +9 more
Oct 16, 2021